Fulcrum Therapeutics (FULC) Free Cash Flow (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Free Cash Flow data on record, last reported at -$18.8 million in Q1 2026.

  • On a quarterly basis, Free Cash Flow fell 22.95% to -$18.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$63.9 million, a 945.09% decrease, with the full-year FY2025 number at -$60.4 million, down 2319.03% from a year prior.
  • Free Cash Flow reached -$18.8 million in Q1 2026 per FULC's latest filing, down from -$17.0 million in the prior quarter.
  • Over the last five years, Free Cash Flow for FULC hit a ceiling of $58.9 million in Q2 2024 and a floor of -$28.7 million in Q2 2022.
  • A 5-year average of -$15.9 million and a median of -$19.2 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 379.56% in 2024, then crashed 123.46% in 2025.
  • Tracing FULC's Free Cash Flow over 5 years: stood at -$17.9 million in 2022, then dropped by 29.99% to -$23.2 million in 2023, then grew by 27.44% to -$16.9 million in 2024, then dropped by 0.56% to -$17.0 million in 2025, then dropped by 10.65% to -$18.8 million in 2026.
  • Business Quant data shows Free Cash Flow for FULC at -$18.8 million in Q1 2026, -$17.0 million in Q4 2025, and -$14.3 million in Q3 2025.